BACKGROUND: Nivolumab is a new standard of care for patients with metastatic renal cell carcinoma (mRCC) and provides an overall survival benefit of 5.40 months in comparison with everolimus. This study evaluated the cost-effectiveness of nivolumab for the second-line treatment of mRCC from the perspective of US payers and identified the range of drug costs for which the addition of nivolumab to standard therapy could be considered cost-effective from a Chinese perspective. METHODS: A partitioned survival model was constructed to estimate lifetime costs, life-years, and quality-adjusted life-years (QALYs). Costs were estimated for the US and Chinese health care systems. One-way and probabilistic sensitivity analyses were performed. RESULTS: Nivolumab provided an additional 0.29 QALYs at a cost of $151,676/QALY in the United States. The probabilistic sensitivity analysis showed that at a willingness-to-pay threshold of $100,000/QALY, at the current cost of nivolumab, the chance of nivolumab being cost-effective was 3.10%. For China, when nivolumab cost less than $7.90 or $9.70/mg, there was a nearly 90% likelihood that the incremental costeffectiveness ratio for nivolumab would be less than $22,785 or $48,838/QALY, respectively. CONCLUSIONS: For the United States, nivolumab is unlikely to be a high-value treatment for mRCC at the current price, and a price reduction appears to be justified. In China, value-based prices for nivolumab are $7.90 and $9.70/mg for the country and Beijing City, respectively. This study could and should inform the multilateral drug-price negotiations in China that may be upcoming for nivolumab. Cancer 2017;123:2634-41.
INTRODUCTION
Renal cell carcinoma (RCC) is the most common type of kidney cancer, with 9 of 10 kidney cancers being RCC. In 2015, it was estimated that 66,800 new cases of kidney cancer were diagnosed and that 23,400 patients died of this disease in China. 1 Although the number of diagnoses of kidney cancer in the United States is similar to the number in China (62,700 in 2016), the number of deaths from this disease are approximately half the number in China (14,240 in 2016) . 2 RCC has a poor prognosis, and up to 17% of patients have advanced disease at the time of their diagnosis, partly as a result of the lack of early symptoms. 3, 4 Over the past years, great advances have been made in the treatment of metastatic renal cell carcinoma (mRCC), and multiple targeted therapies, including vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin inhibitors, are available for the treatment of mRCC. Everolimus, a mammalian target of rapamycin inhibitor, provides a significant benefit in progression-free survival (PFS) in comparison with a placebo for patients with mRCC whose disease progresses after sunitinib or sorafenib. 5 Although everolimus is the current standard of care for patients with mRCC for whom 1 or more lines of VEGF-targeted therapy have failed, 6 the agent offers only limited overall survival (OS).
Nivolumab is a fully human immunoglobulin G4 monoclonal antibody that binds to the programmed death 1 receptor and restores T-cell immune activity. 3 A pivotal, randomized, phase 3 trial of second-line treatment in patients with mRCC (CheckMate 025) demonstrated a median OS benefit of 5.4 months for nivolumab in comparison with everolimus (hazard ratio, 0.73; 95% confidence interval, 0.57-0.93; P 5 .002). 7 Nivolumab was associated with a lower incidence of grade 3 or 4 adverse events (AEs) than everolimus (19% vs 37%). Nivolumab has altered the landscape of mRCC treatment and has been recommended for patients for whom 1 or more lines of previous VEGF-targeted therapy have failed; it is the new standard of care for patients. 6 The excitement in the oncology community about the significant OS improvements for patients from nivolumab has been accompanied by the concern that the widespread use of nivolumab may lead to a dramatic increase in health care costs because of the high cost of the drug. 8 Because nivolumab has recently been approved by the US Food and Drug Administration for mRCC, 9 an economic evaluation from the US-payer perspective would be useful for informing decision makers about the value and benefits of using nivolumab for patients with mRCC. Although nivolumab is not approved by the China Food and Drug Administration (CFDA), a phase 3 trial for nivolumab has been approved in China, and we expect that it will be approved in the foreseeable future. Once the CFDA approves nivolumab, widespread use of the drug may substantially increase the costs of cancer care. Therefore, we have performed a prospective assessment to identify the range of drug costs from a Chinese perspective within which the addition of nivolumab as a second-line treatment for mRCC could be considered cost-effective.
MATERIALS AND METHODS
The model structure included 3 health states to represent the progression of mRCC: PFS, progressive disease, and death ( Fig. 1) . Patients in the PFS state were treated with nivolumab or everolimus until progression. Upon progression of the disease, both groups could receive postprogression treatment until death.
We developed a partitioned survival model with the R software package (http://www.r-project.org) to determine state populations in each cycle of the model according to the approach of Hoyle et al. 10 The number of patients who were in the PFS state or dead at any time was determined directly from the underlying survival curves, and the number of patients with progressive disease was calculated as OS minus PFS.
The model cycle length was 2 weeks because nivolumab was administered every 2 weeks. We adopted a 3% discount rate per year for both costs and outcomes. The primary outputs of the models included the total cost, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Costs were estimated separately for US payers and the Chinese health care system. Only direct medical care costs were considered in the model. All costs in this study are reported in 2014 US dollars with an exchange rate of US $1 5 6.50 Chinese yuan (May 2016).
Patients and Intervention
Our treatment schema was modeled after the CheckMate 025 trial. 7 Eligible patients had measurable mRCC according to the Response Evaluation Criteria in Solid Tumors (version 1.1) and had received 1 or 2 previous regimens of antiangiogenic therapy. Patients were randomly assigned to receive nivolumab or everolimus. 7 
Model Survival and Progression Risk Estimates
The estimates of OS for treatment with nivolumab and everolimus were based on the results of the CheckMate 025 trial. 7 First, the GetData Graph Digitizer software package (version 2.25; http://www.getdata-graph-digitizer.com/index.php) was used to extract the OS probabilities from the published Kaplan-Meier curves reported by Motzer et al. 7 A Weibull distribution was fitted separately to these data because Weibull distributions are flexible and are widely used in cancer survival analyses. Next, the shape parameter (c) and the scale parameter (k) were estimated from this fit to the Kaplan-Meier curves with the method of Hoyle et al, 11 and the mean OS time was estimated as follows:
where C(c) is the gamma function. This method provides more accurate estimates of the mean survival time, which are essential for a cost-effectiveness analysis. 11, 12 Finally, the OS rates in each cycle were estimated as exp(-kt c ), where t is survival time.
We estimated the PFS rate for each arm with the same approach.
Utility Estimates
The EuroQol-5 Dimensions (EQ-5D) instrument was used in the CheckMate 025 trial to collect health-related quality-of-life (QOL) data. 13 In the trial, the EQ-5D index score was 0.78 (standard deviation, 0.24) and 0.78 (standard deviation, 0.21) for patients receiving nivolumab and patients receiving everolimus before treatment initiation (baseline), respectively. The change from the baseline in the EQ-5D index score was measured on day 1 of each cycle during the treatment period in the study by Cella et al. 13 In the model, changes from the baseline in the EQ-5D index score of 0.068 (range, 0-0.149) for the nivolumab group and-0.028 (range, -0.132 to 0.003) for the everolimus group were used; these were the averages of the changes from the baseline reported. Therefore, utilities of 0.848 and 0.752 were assigned to patients receiving nivolumab and everolimus, respectively. 13 Because the experiences of patients in treatment were reflected in the utilities and, therefore, treatment-related AEs were included in the utilities, additional utility decrements associated with AEs were not modeled. A utility value from a previously published economic evaluation was used to estimate the utility during postprogression treatment, regardless of the treatment composition (Table 1) .
Cost Estimates
Direct medical costs for the PFS health state included drug, administration, and AE costs. The dosage regimen for nivolumab in the CheckMate 025 trial was 3 mg/kg intravenously every 2 weeks; however, the US Food and Drug Administration has modified the dosage regimen to 240 mg intravenously every 2 weeks for all patients with RCC without a clinically meaningful effect on safety and efficacy. 24 Drug-treatment costs for the PFS state were based on the following schedules: 240 mg of intravenous nivolumab over a 60-minute period every 2 weeks or 10 mg of everolimus once per day.
We included grade 3 or 4 AEs that occurred in more than 5% of the patients and with a difference of more than 4% between treatments in the pivotal trial 7 because these may be regarded as important risks of drug treatment. These included anemia, stomatitis, and hypertriglyceridemia. The incidence rates of AEs in the model were derived from the CheckMate 025 trial. Hypertriglyceridemia was assumed to be managed with fenofibrate at 145 mg daily in the outpatient setting on the basis of a recently published study. 21 As observed in the CheckMate 025 trial, 7 55% of the patients in the nivolumab group and 63% in the everolimus group received subsequent systemic therapy after disease progression. Among patients in the nivolumab group, 44% received everolimus, 41% received axitinib, and 15% received pazopanib; among patients in the everolimus group, 59% received axitinib, 25% received pazopanib, and 16% received sorafenib. The following dosing strategies were used: 800 mg of sorafenib once per day, 5 mg of axitinib twice per day, and 800 mg of pazopanib once per day.
In accordance with the approach of Goldstein et al, 25 administration costs for the United States were calculated with the Medicare physician fee schedule for 2014. Because pazopanib is not marketed in China, the Hong Kong listed price was used in the base-case analysis. All the unit costs are listed in Table 1 . Costs from past sources were adjusted to 2014 US dollars according to the US and Chinese consumer price index health care services groups, respectively.
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Sensitivity Analysis
We conducted sensitivity analyses to explore how results varied across plausible ranges. One-way sensitivity analyses were conducted for the United States with 95% confidence intervals for parameters or with plausible ranges (if no confidence intervals were available). Probabilistic sensitivity analyses were conducted with 1000 second-order Monte Carlo simulations, in which the parameters were simultaneously varied with a specific pattern of statistical distribution: a c distribution was adopted for all input costs and the mean survival time, and a b distribution was used for the utilities. For the United States, we present cost-effectiveness acceptability curves comparing nivolumab and everolimus for different costs of nivolumab. For China, curves that represent the probability of the ICER being below the willingness-to-pay (WTP) thresholds for different costs of nivolumab are presented.
Variations in the Cost of Nivolumab
The base-case model was run multiple times with different costs of nivolumab to determine the effect on the ICER; ICERs below the WTP thresholds for the United States and China are presented.
RESULTS
Base-Case Results
Over the 20-year time horizon, the model projected that the life expectancy of patients receiving nivolumab would be 2.435 LYs, which was 0.301 LYs longer than the life expectancy of patients receiving everolimus. When we accounted for QOL, patients receiving nivolumab gained 1.786 QALYs; this value was 0.29 QALYs more than that for patients receiving everolimus. In the United States, the use of nivolumab cost an additional $44,002, and this resulted in an ICER of $145,940/LY or $151,676/QALY in comparison with everolimus (not shown). When nivolumab cost $9.02 and $10.58/mg in China, the ICERs approximated the WTP thresholds of $22,785 and $48,838/QALY, respectively. When nivolumab cost $22.50/mg in the United States, the ICER approximated the WTP threshold of $100,000/QALY (Table 2) . Figure 2 and Supporting Figure 1 (see online supporting information) present the impact of uncertainty in model inputs on the expected outcomes for the United States with and without adjustments for QOL, respectively. The results were most sensitive to the costs for nivolumab. When the cost of nivolumab was reduced to 80% of the baseline, the ICER fell to $63,861/LY or $66,371/QALY. When the cost of nivolumab was increased to 120% of the baseline, the ICER was $227,928/LY or $236,949/ QALY. Across the broad variation in the ranges for all parameters other than the cost of nivolumab, the ICERs were greater than the US WTP threshold of $100,000/ QALY.
Sensitivity Analysis
The results of probabilistic sensitivity analyses for the United States, shown in the cost-effectiveness acceptability curves in Figure 3 , suggest that at a WTP threshold of $100,000/QALY, the probability that nivolumab would be cost-effective was 3.10%, 74.30%, and 100% when nivolumab was priced at full cost, 85% of the cost, and 60% of the cost, respectively. For China, Figure 4 demonstrates that when nivolumab cost less than $7.90 or $9.70/mg, there was a nearly 90% likelihood that the ICER for nivolumab would be less than $22,785 or $48,838/QALY, respectively. When the price of nivolumab was greater than $14/mg, the probability that the ICER would exceed WTP thresholds in China was 100%. When we did not account for QOL, at a WTP threshold of $100,000/LY, the probability that nivolumab would be cost-effective in the United States was 4.90%, 76.00% and 100% when nivolumab was priced at full cost, 85% of the cost, and 60% of the cost, respectively (Supporting Fig. 2 [see online supporting information]). In China, when nivolumab cost less than $8.20 or $9.80/mg, there was a nearly 90% likelihood that the ICER for nivolumab would be less than $22,785 or $48,838/LY, respectively (Supporting Fig. 3 [see online supporting information]).
DISCUSSION
The global cost of cancer care has been growing rapidly, and the introduction of costly new anticancer drugs has contributed much to this trend. 28 Ceritinib costs approximately $13,000/mo for the treatment of metastatic lung cancer. 29 A combination of checkpoint inhibitors (ipilimumab and nivolumab) can cost as much as $100,000/mo. Although the increase in drug prices might be justified if new agents provided more benefits than old ones, how much should we pay for these incremental benefits? Unfortunately, there is no association between the magnitude of the clinical benefit and the drug price, 28 and a large amount of money has been spent on cancer treatments without clinically meaningful benefit. Recently, the American Society of Clinical Oncology chose clinical benefits, toxicity, and cost to define the value of cancer care. 31 The European Society for Medical Oncology developed a tool to quantify clinical benefits of cancer treatments to obtain an objective definition of clinical benefit that can be related to cost. 32 All these efforts are helpful for ensuring that a drug's price reflects its potential benefit and the best use of limited resources; this is called value-based pricing, 28,33 a method for developing pricing strategies for new drugs based on cost-effectiveness analysis.
Our study is the first model-based analysis to evaluate the health and economic outcomes of nivolumab for the second-line treatment of patients with mRCC from the United States and the first prospective evaluation to establish a cost for nivolumab such that it would be considered cost-effective from a Chinese perspective. In the United States, our base-case estimate of the ICER for nivolumab versus everolimus ($145,940/LY or $151,676/ QALY) was above the WTP threshold of $100,000/ QALY, 34 and the probability of nivolumab being costeffective at the current cost was low (3.10%); this suggests that nivolumab is unlikely to be a high-value treatment for mRCC. Although nivolumab is not cost-effective for the United States at the current price with the WTP threshold of $100,000/QALY, because of the OS benefit and tolerability of nivolumab over everolimus, nivolumab should not be overlooked. Because our study shows that the results are very sensitive to the price of nivolumab, a reduction in price by negotiation regarding tradeoffs between the drug price and coverage may be an appropriate and effective method to improve the cost-effectiveness. If the cost were reduced by 13%, the ICER would be below the WTP threshold. A cost reduction of nivolumab by 40% would improve the probability of nivolumab being cost-effective to 100% (Fig. 3) .
Currently, there is no official cost-effectiveness threshold in China, so we used the WTPs of 3 times the per-capita gross domestic product of China in 2014 ($22,785) and 3 times the per-capita gross domestic product of Beijing City in 2014 ($48,838) as the threshold values in accordance with the World Health Organization guidelines. 35, 36 When nivolumab cost less than $7.90 or $9.70/mg in China, there was a nearly 90% likelihood that the ICER for nivolumab would be less than $22,785 or $48,838/QALY, respectively. The patent drug prices, which are freely set by the manufacturers, are high and have been a challenge for Chinese patients to afford. As a result of the new drug-pricing reform initiated in 2015, the pricing mechanisms for patented drugs have gradually changed into multilateral negotiations involving the pharmaceutical industry and other stakeholders. 37 In 2016, the prices of 3 patent drugs (tenofovir disoproxil, icotinib, and gefitinib) were reduced by more than 50% after multilateral negotiations. 38 Because negotiations regarding tradeoffs between drug prices and coverage based on costeffectiveness analyses could lead to improved outcomes for both health-care systems and manufacturers, 33 valuebased pricing-based negotiations should play an important role in China. In January 2017, when the state council issued its 13th 5-year plan for deepening medical and health care system reform, it stated that economic evaluation would be an important part of multilateral negotiations. 39 Therefore, the results of our study could and should inform the multilateral drug-price negotiations in China that may be upcoming for nivolumab, and we hope that the results can help to promote this change in the drug-pricing mechanism. In China, a country with scarce health resources, a novel governmental agency such as the National Institute of Health and Care Excellence in the United Kingdom could be created to legislate maximum pricing after regulatory approval by the CFDA to ensure the best use of the limited resources. Recently, the final results of the phase 3 METEOR trial showed that cabozantinib significantly improved OS and PFS in comparison with everolimus for previously treated patients with mRCC. 40 The value of cabozantinib with respect to its benefit is unknown; however, nivolumab and cabozantinib changed the treatment paradigms for VEGF-targeted therapy-refractory RCC and created a new a standard for the majority of patients with mRCC. Investigations of the optimal use of nivolumab, cabozantinib, and other available treatments might help to provide the maximum benefit to patients with mRCC and to improve the cost-effectiveness.
There are several limitations to our analysis that deserve consideration. First, the costs of subsequent therapy after disease progression were estimated according to information published for the CheckMate 025 trial, which may differ from clinical practice in China. Although the costs have some impact on the results in China, the results of the sensitivity analysis indicate that the influence is limited. Second, we did not model the additional costs for all AEs incurred in the PFS state. We do not expect that the inclusion of all AEs would change the conclusions of the study because small cost differences associated with AEs would be practically negligible. Third, the utility values for Chinese patients were assumed to be equivalent to those for patients in the West. Although this may not reflect Chinese data, we have accounted for actual variations in QOL with the range of utility values used in the sensitivity analyses. It has been reported that the QOL of patients with mRCC in China is not significantly different from that of patients from Western countries. 20 Fourth, our model-based study did not have access to data for individual patients from CheckMate 025, which would have allowed more precise survival estimates. A trial-based analysis could be performed to confirm the results when the raw data from CheckMate 025 are available. The survival benefits, however, were estimated with the method of Hoyle et al 11 in our study; this gives more accurate curve fits than the least squares method and the regression method and estimates the mean survival time, which is essential for a costeffectiveness analysis, almost as precisely as an analysis of data for individual patients. 12 In conclusion, for the United States, nivolumab is unlikely to be a high-value treatment for mRCC, and a price reduction appears to be justified. For China, our study shows that value-based prices for nivolumab would be $7.90 and $9.70/mg for the country and Beijing City, respectively. The results of our study could and should inform the multilateral drug-price negotiations in China that may be upcoming for nivolumab.
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